We’re heading to the Jefferies Biotech on the Bay Summit in Miami on March 12, 2024. The ProKidney management team looks forward to hosting one-on-one meetings. For additional details, please read our full press release here https://lnkd.in/eNwSTewg
ProKidney Corp.’s Post
More Relevant Posts
-
Private Equity Professional | Helping Performance Materials Companies Grow | Unlocking & Enabling Potential
Thank you for including me! Thought-provoking discussion! The persistence of the key longer-term trends driving the life science sector remain clear and robust. That said, our conversation really drove home the impact of the capital markets on our industry. Much of "Big Pharma" is undergoing significant reorgs and valuation metrics are down meaningfully YoY. Similarly, VC funding for emerging and virtual companies is "difficult" to say the least....funding availability, terms, cap table challenges, etc. ....left wondering if large pharma steps up to fill the liquidity / capital gap. If not, it might take some time to work through this period of adjustment... #CPHIBarcelona #InvestorInsights #LifeSciences #CapitalMarkets #BigPharma
In case you were unable to attend, a key event at CPHI Barcelona was the Investor Roundtable, 'Igniting Innovation in Catalonia and Beyond'. This closed-door event brought together a wide investor network to discuss the benefits and challenges of investing in the vibrant Catalonian pharmaceutical industry. The discussion was moderated by Mark Robbins, Co-Founder of Catalonia-based SugaROx and Senior Advisor at CCD Partners, who posed several questions to representatives of private equity and venture capital firms. We heard from a range of participants, including Bob Girton, Partner at Edgewater Capital Partners, and Anton Holm, Senior Associate at Waterland Private Equity, who contributed to a dynamic discussion and exchanged innovative ideas. #CPHIBarcelona #InvestorRoundtable #PrivateEquity #Catalonia
-
Inspiring Science, Inspiring Teamwork, Inspiring Entrepreneurship @argenx . See below for the full interview with our CEO Tim Vanhauwermeiren.
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
-
📰 Weekly Healthcare & Life Sciences transactions selection: GREENPEAK Partners-backed Paratus (🇩🇪) secures majority ownership in DB Soft (🇪🇸). Resolve Stroke (🇫🇷) raises €2.2m with Quantonation and OVNI Capital. Broken String Biosciences (🇩🇪) closes $15M Series A Funding Round co-led by Illumina Ventures and Merieux Equity Partners. Pharmanovia (🇬🇧) acquire 11 central nervous system brands from Sanofi (🇫🇷). ReCode Therapeutics (🇺🇸) announced the closing of an extension to its Series B financing, raising an additional $50m with new investor Bioluminescence Ventures and Solasta Ventures. MCH Private Equity has invested in FARMALIDER GROUP (🇪🇸). REEV (techstars '23) (🇫🇷) raises €3m from Polytechnique Ventures, IRDI Capital Investissement, and Newfund. Search your next deal among #privateequity #investments and millions of company profiles on Tsylana app for #investmentbanking #corporatefinance and #capitalinvestissement professionals.
-
Navigate the ins and outs of strategic industry partnerships with Adam Hostetler, Director of Business Operations at Cook MyoSite, in this upcoming webinar! Register for free and uncover key strategies and best practices for developing a successful biotech partnership >>> https://hubs.ly/Q02xfyJR0
-
In the latest episode of Exceptional Leaders / Exceptional Ideas, our CEO Tim Van Hauwermeiren discusses his entrepreneurial journey, navigating the launch of argenx, and our approach to developing innovative treatments for autoimmune conditions. Watch the full episode below.
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
-
R&D, Drug Development & Medical Affairs, Market Access Global Clinical Studies and Product Marketing Lifecycle Management across the Globe
Not easy to start a new company
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
-
What do biotech investors look for when considering a deal? Strong leadership, strategic foresight, financial efficiency, and deep industry knowledge are all key deciding factors. Curious to learn more? Gain invaluable insights on M&A advisory and investor decision-making from Bracken Managing Partner, James Gilligan, in this blog post: https://lnkd.in/eMzHrtpx #LifeSci #Biopharma #Investing #DueDiligence #Bracken
Biotech Investors: Who They Are & What They Want
thebrackengroup.com
-
Optimising operations will help biotechs facilitate movement through critical milestones, avoid delays and help navigate this most difficult program phase. Learn how biotech sponsors can mitigate costly, time-consuming changes by simplifying protocol design in part two of our biotech funding whitepaper series. https://ow.ly/ZyUc50RrXHn
-
-
Dealmaking has hit biopharma front and center this year. 2024 is off to a great start with all the M&A and BD deal announcements leading up to the J.P. Morgan Healthcare Conference. With all the trials and tribulations biotech founders go through, M&A shines as the bright light at the end of the tunnel. Of course the announcements are the tip of the iceberg. A milestone achieved after months of engagement to find the right fit and the right partner. If you have been following the space or looking for a recap, here is a list of deals announced so far this month. Here's to hoping for many more successful M&A exits this year! #biotech #biopharma #dealmaking #jpm2024
-
-
Excited to share insights from a dynamic discussion featuring GRETCHEN COOK-ANDERSON, Executive Director of LabCentral Ignite! At the Boston Globe Media they dove into Boston's vital role in global biotech and pharmaceutical innovation, touching on key topics like recent layoffs and efforts to boost diversity. Plus, they talked about how to attract and keep talent, and how the demand for lab space in the area is changing. Keep an eye out for updates on how Ignite is shaping Boston's biotech scene! Check out the conversation here! ➡ https://lnkd.in/eK_YUnr7 #BiotechInnovation #BostonBiotech #DiversityInTech #TalentAcquisition #LabSpace #IgniteImpact #LinkedInDiscussion
-
